期刊文献+

托瑞米芬治疗重症乳腺增生症的临床研究 预览 被引量:8

Clinical Study on Toremifene in the Treatment of Mammary Gland Hyperplasia
在线阅读 免费下载
收藏 分享 导出
摘要 目的 观察枢瑞(国产托瑞米芬)治疗乳腺增生病的临床疗效及安全性。方法 从我院门诊患者中选取符合条件的患者50例,口服枢瑞40mg/d,饭后服药,至下次月经来潮,经期停药。治疗3个疗程。观察治疗前后,疗效、血清性激素及血脂;肝功能:SCOT、SGPT;血脂变化;B超、钼靶片、CT检查腺体厚度、结构等变化。结果 总有效率为90%,明显促进腺体退化;并能调整机体内源性激素水平,改善乳腺慢性增生的病变过程。结论 托瑞米芬治疗乳腺增生病安全有效。 Objective To observe the therapeutic effect and side effects of Toremifene(TOR)in women with hyperplasia of mammary gland (HMG) and meanwhile test blood sex hormones and blood lipid levels. Methods 50 severe FIMG patients(age range 34 - 50 years)with a mean age of 43.6 years, were selected from outpatient service of our section during November, 2004 to November,2005. TOR 40mg/d was taken orally after dinner, total course lasting 3 months but no medication during menstruation. Clinical observation including therapeutic effect, sex hormone level, serum lipid level, liver function, thickness of mammary gland, constitution of the gland, etc. were also made before and after the treatment. Results TOR could not only cure HMG, but also regulate sex hormone secretion in HMG patients. Clinical study showed that the total effective rate was 90 %, with a significant difference in comparing with the control group, ( P 〈 0.05) ; while progestogen and testosterone increased significantly (P 〈 0.05) ; but no significantly change of follicle stimulating hormone and luteinizing hormone was found. TOR showed marked effect in treating and preventing HMG, it could modulate sex hormone, and improve the construction of mammary gland. Toremifene decreased cholesterol and LDL cholesterol and triglyceride levels by 9.0 %, 10.1% and 9.7 % respectively. Conclusion TOR is an effective agent in the treatment of HMG, and accelerate the deterioration of mammary gland significantly. TOR can adjust the endogenous sex hormone level, delay the development of chronic serious hyperplasia of mammary gland. TOR also improves all lipoproteius that are associated with increased coronary heart disease (CHD)risk.
作者 孙学民 王培军 童晓文 SUN Xue-min, WANG Pei-jun, TONG Xiao-wen ( 1. Dept. of Obs & Gyn, Tongji Hospital, affiliated to Tongji University, Shanghai 200065, China; 2. Dept. of Radiology, Torsi Hospital, affiliated to Tongji University, Shanghai 200065, China)
出处 《同济大学学报:医学版》 CAS 2006年第5期 58-61,共4页 Journal of Tongji University(Medical Science)
关键词 托瑞米芬 乳腺增生 疗效 toremifene hyperplasia of mammary gland clinical study
作者简介 孙学民(1972-),女,主治医师.E-mail:sunnie991059yahoo@.com.cn
  • 相关文献

参考文献5

  • 1李树玲主编..乳腺肿瘤学[M].北京:科学技术文献出版社,2000:698.
  • 2Kusama M,Miyauchi K,Aoyama H,et al.Effects of toremifene (TOR) and tamoxifen (TAM) on serum lipids in postmenopausal patients with breast cancer[J].Breast Cancer Res Treat,2004,88(1):1-8. 被引量:1
  • 3中国中医药学会外科乳腺病专业委员会.乳腺增生病诊断、辨证及疗效评价标准[S].2001.121. 被引量:10
  • 4Gonzalez-Perez J,Crespo MJ.Chronic effects of toremifene on the vasculature of menopause-induced rats[J].Vascul Pharmacol,2003,40(5):261-268. 被引量:1
  • 5Hamed H,Kotheri A,Beechey-Newman N,et al.Toremifene,a new agent for treatment of mastalgia:an open study[J].Int J Fertil Womens Med,2004,49(6):278-280. 被引量:1

共引文献9

同被引文献70

引证文献8

二级引证文献41

投稿分析

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部 意见反馈